Pharmacogenetics and drug development: the path to safer and more effective drugs.
about
Chapter 7: PharmacogenomicsSequence variation in G-protein-coupled receptors: analysis of single nucleotide polymorphismsIdentifiability in biobanks: models, measures, and mitigation strategiesThe path from genome-based research to population health: development of an international public health genomics networkLocal Adaptation of Sun-Exposure-Dependent Gene Expression Regulation in Human SkinA network-heuristic approach to improve the impact of genomic data on drug discovery.Pharmacogenomic data sample collection and storage: ethical issues and policy approaches.Satisfaction survey with DNA cards method to collect genetic samples for pharmacogenetics studiesDopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder.Phenotype prediction using regularized regression on genetic data in the DREAM5 Systems Genetics B Challenge.Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.Applying genome-wide gene-based expression quantitative trait locus mapping to study population ancestry and pharmacogeneticsPharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.Pharmacogenetics in drug development.Bioinformatics challenges for personalized medicineVIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension.Pharmacogenomics in pulmonary arterial hypertension: Toward a mechanistic, target-based approach to therapy.Polymer genomics: an insight into pharmacology and toxicology of nanomedicinesIntegrative Analysis of Response to Tamoxifen Treatment in ER-Positive Breast Cancer Using GWAS Information and Transcription ProfilingGenomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics.Emerging strategies and applications of pharmacogenomicsPharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.Priorities and standards in pharmacogenetic research.Novel technology and the development of pharmacogenetics within the pharmaceutical industry.A pharmacogeneticist's look at drug effects and the drug development process: an overview.Pharmacogenomics and therapeutic prospects in Alzheimer's disease.Pharmacogenetics/genomics and personalized medicine.Genetics of drug resistance.Use of genomic signatures in therapeutics development in oncology and other diseases.Visualizing gene determinants of disease in drug discovery.A public health approach to pharmacogenomics and gene-based diagnostic tests.Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration.AmpliChip CYP450 test: personalized medicine has arrived in psychiatry.From genomics to drug targets.Theragenomic knowledge management for individualised safety of drugs, chemicals, pollutants and dietary ingredients.Pharmacogenetics of antiarrhythmic therapy.Genetic association studies in epilepsy pharmacogenomics: lessons learnt and potential applications.Emerging patent issues in genomic diagnostics.Pharmacogenomics: challenges and opportunities
P2860
Q21563496-78C4479C-F79C-4988-9A29-8876476C155EQ24804913-D9185FC3-5067-447B-B3F6-6D8740ABA344Q27010356-EFF460CA-5CBF-4455-B739-E7C1E29C7CEFQ28252405-96BD42DD-03BA-45C3-9977-719639BF5D24Q28597150-1CC03DCF-EE49-404C-B179-69914FB4E363Q30603977-B2F9BE2A-ABCB-4BFB-B2D2-E6CE133144C0Q31033583-F401A2F7-2BB8-4028-BA7A-66A062DF79BCQ33242717-FB64FC6C-BA76-43F5-9BF9-67CD5E02E4F2Q33799533-34E13732-DE24-420C-915F-B0A0BFE698E1Q34117193-EAAFCDFB-F307-405D-AD0B-9651EF00F803Q34131354-9F656DF0-EEEC-46B4-978B-84ACC53E433AQ34146222-027C8552-66ED-4D2D-B112-A7BC583CFCCFQ34539515-D1803CD5-1AE3-4C6A-9800-3A104935B19DQ34982551-01393231-0D1B-4443-9F19-4CE006C6FA04Q35038056-BEDFF11D-AB86-4910-A114-B7ADA35C8580Q35051893-B6A9B267-ECF3-494A-8EC6-215D8AC5EF57Q35533520-6BBB92BE-B115-4224-99E9-49734DBA87AFQ35573944-E02725FB-90D8-409B-BEC8-9971941CC1D3Q35754353-CA41235D-F3B3-4839-8CAE-B8DBA75AA02EQ35799611-4E7BC421-C981-488D-892C-60B30CCE2408Q35852564-53F2BEBB-5099-4C07-A495-332820CA51BEQ35988130-81DB7F4B-FE63-4A39-94A6-961119B07151Q36120821-A0097F31-84E4-4F70-92CA-96D7A1137AFBQ36180606-DE18879C-64AA-46C5-951E-70C0FA29B2EFQ36186950-A66762CB-B7E1-4F1F-AFBD-968C2DA36080Q36192744-951CA107-9EC2-425F-9E05-C7B4573FA0B7Q36273420-C60B0967-181E-44BF-A4FB-FDAE3F5E0A0AQ36294685-9F3CEAD1-13CF-4220-AE24-21AA52EE31FFQ36344243-822F0DF8-0195-487F-8FF6-2ECA6C6F4532Q36369836-36510998-B97E-46A4-B14A-AF2CFF867760Q36446867-DCD449A5-A676-4BB0-BF1B-0DB6C9FCBE35Q36446871-A3920FB2-2902-4AE6-96B8-0228032937BBQ36465191-1C669E54-D2D6-4510-AEAD-19D5626CB61EQ36481089-AD2AFBF8-CA38-43E3-9D68-F61696C00103Q36511712-6336BE23-AD44-4E7F-BD83-437DD2970AFAQ36545002-2A988C56-7A56-4F9A-B5E9-7933667B55C8Q36548713-D595E783-E1C3-49BF-86E7-BFB008F04EB2Q36555922-A63E224B-7730-4508-B6EA-0C315AE7B0A2Q36561630-A3521E33-FD1F-4A4B-BA8D-8A761C748F25Q36658763-93F8EF86-39A0-4532-9121-E19661A3D342
P2860
Pharmacogenetics and drug development: the path to safer and more effective drugs.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Pharmacogenetics and drug development: the path to safer and more effective drugs.
@ast
Pharmacogenetics and drug development: the path to safer and more effective drugs.
@en
type
label
Pharmacogenetics and drug development: the path to safer and more effective drugs.
@ast
Pharmacogenetics and drug development: the path to safer and more effective drugs.
@en
prefLabel
Pharmacogenetics and drug development: the path to safer and more effective drugs.
@ast
Pharmacogenetics and drug development: the path to safer and more effective drugs.
@en
P2860
P356
P1476
Pharmacogenetics and drug development: the path to safer and more effective drugs.
@en
P2093
Allen D Roses
P2860
P2888
P304
P356
10.1038/NRG1432
P577
2004-09-01T00:00:00Z